What is Sentrimed?
Sentrimed operates at the intersection of biotechnology and precision medicine, specializing in the development of novel, targeted therapies. The company leverages a sophisticated, IP-protected platform designed to modulate cell-to-cell communication, effectively identifying and neutralizing abnormal cells. By focusing on biomarker-driven oral medications, Sentrimed addresses critical unmet needs in the treatment of aggressive malignancies. Its strategic approach emphasizes the immobilization and elimination of tumor cells across the entire care continuum, positioning the firm as a significant player in the next generation of cancer therapeutics.
How much funding has Sentrimed raised?
Sentrimed has raised a total of $250K across 1 funding round:
Debt
$250K
Debt (2026): $250K, investors not publicly disclosed
Key Investors in Sentrimed
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Sentrimed?
With this latest capital injection, Sentrimed is expected to prioritize the expansion of its clinical pipeline and the scaling of its research operations. The company will likely focus on advancing its lead candidates through rigorous clinical trials while strengthening its intellectual property portfolio. As it transitions into a more mature phase of development, Sentrimed will likely seek to optimize its biomarker-driven delivery systems, potentially exploring strategic partnerships to integrate its oral medications into broader combination therapy regimens. This growth phase is critical for validating the efficacy of its platform in real-world clinical settings and establishing a sustainable competitive advantage in the global oncology market.
See full Sentrimed company page
